Leerink Partnrs Has Bearish Estimate for FULC Q1 Earnings
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Fulcrum Therapeutics in a research note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.35) for the […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Fulcrum Therapeutics in a research note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.35) for the […]
